Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease
Brief Summary: The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.


Options:
A: Arm Label: Population 1: Placebo SC followed by ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Ustekinumab SC followed by Placebo SC:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Placebo IV followed by ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 1: Ustekinumab IV followed by Placebo IV:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 2: Ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg | Arm Label: Population 2: Ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC:, Population 2: Ustekinumab SC | Intervention Type: DRUG; Name: Ustekinumab 4.5 mg/kg; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:, Population 2: Ustekinumab IV | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC: | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:
B: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
C: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: A